1 min read
Add as a preferred source on GoogleVertex Pharmaceuticals Raises 2026 Revenue Guidance After Mixed Q3
The new range tops out below the $13.28 billion consensus estimate, as quarterly revenue beat estimates and the bottom-line result missed.
Vertex Pharmaceuticals raised its 2026 revenue guidance to $13.15 billion to $13.25 billion, lifting both ends of its previous $13.1 billion to $13.2 billion range. The new high end remains below the $13.28 billion consensus estimate.
The updated outlook follows mixed third-quarter results: revenue exceeded estimates, while the bottom-line result fell short.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.